Cost Analysis of Chronic Urticaria Management in Latin America
Author Information
Author(s): Jorge Sánchez, Leidy Álvarez, José Ignacio Larco, Luis Ensina, Guillermo Guidos‐Fogelbach, Cesar Reyes‐López, German D. Ramon, Karla Robles‐Velasco, Ivan Cherrez‐Ojeda
Primary Institution: Group of Clinical and Experimental Allergy, University of Antioquia
Hypothesis
What are the economic diagnostic and therapeutic expenses of chronic spontaneous urticaria in five Latin American countries?
Conclusion
The cost of chronic spontaneous urticaria in Latin America varies widely based on health insurance coverage and therapy costs.
Supporting Evidence
- Brazil had the highest urticaria cost per patient/year at 7009.4 USD.
- Colombia had the lowest cost per patient/year at 2392.8 USD.
- Costs of omalizumab and antihistamines significantly influenced total costs across countries.
- Out-of-pocket expenses for patients were highest in Ecuador and lowest in Colombia.
Takeaway
This study looked at how much it costs to treat a skin condition called chronic urticaria in five Latin American countries. It found that the costs can be very different depending on where you live and what treatments are available.
Methodology
A noninterventional multicenter cross‐sectional study was conducted using questionnaires and medical record reviews to assess costs and characteristics of CSU patients.
Potential Biases
Potential bias due to reliance on self-reported data and varying healthcare access across countries.
Limitations
The study could not determine out-of-pocket costs for each intervention and made assumptions about CSU prevalence in some countries.
Participant Demographics
Patients from Brazil, Colombia, Ecuador, Mexico, and Peru with chronic spontaneous urticaria.
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website